About this item:

761 Views | 716 Downloads

Author Notes:

Corresponding author: Richard D Rheingans (rrheing@sph.emory.edu)

All authors were involved in the design of the study and interpretation of results.

RR developed the study design, developed the instrument, participated in data analysis, and drafted the manuscript.

ACH conceived the study, developed study design, reviewed instrument, and helped in writing the paper.

MLM helped in design of the study and instrument, assisted in data analysis, and helped in writing the paper.

MM helped in study and instrument design and in writing of paper.

GM assisted in design, adaptation, and implementation of survey instrument and helped in interpretation of results.

DA assisted in design of study and writing of paper.

The authors would like to thank Dr. Jack LaFontant and Jackie Louis-Charles of Hospital Ste. Croix in Leogane, Haiti for their assistance in carrying out the study.

There are no competing interests to declare.


Research Funding:

The study was funded in part by a research grant from the CDC Office of Women's Health.


  • Lymphatic filariasis
  • willingness to pay
  • cost
  • contingent valuation

Willingness to pay for prevention and treatment of lymphatic filariasis in Leogane, Haiti


Journal Title:

Filaria Journal


Volume 3, Number 2


Type of Work:

Article | Final Publisher PDF


Background: Lymphatic filariasis (LF) affects more than 120 million people worldwide. Efforts to eliminate this disease require sustained community participation. This study explores community valuation of LF elimination efforts by estimating household and community willingness to pay (WTP) for the prevention of transmission and treatment of filarial lymphedema in the community of Leogane, Haiti. Methods: A contingent valuation survey was used to assess individual WTP for specific prevention and treatment interventions. A 2-dimensional Monte Carlo simulation was developed to estimate confidence limits in mean WTP and to generate a distribution of WTP for the community, accounting for uncertainty in regression coefficients and variability within the population. Results: Mean WTP was estimated to be $5.57/month/household (95% CL: $4.76, $6.72) to prevent disease transmission, and $491/yr (95% CL: $377, $662) for treatment of lymphedema for one person. Based on the estimated distributions, 7% and 39% of households were not willing to pay for prevention and treatment, respectively. Conclusions: These results suggest that the majority of the community places a positive value on both prevention and treatment of LF. Mean WTP provides a useful monetary estimate of overall societal benefit of LF prevention and treatment programs. However, for interventions which require broad and sustained community participation, the lower end of the distribution of WTP has additional implications. Cost recovery policies may result in inadequate participation and longer program duration.

Copyright information:

© 2004 Rheingans et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.

Export to EndNote